Find the right partners. Close the right deals.
JustPartnering helps biotech and research teams identify, position, and license their assets to the right pharma and biotech partners.
We find who is actively in-licensing in your space, prepare the materials they need to see, and keep every conversation moving until terms are agreed.
Identify the right partners
Who is actively in-licensing in your space
Build a partner-ready pitch
The materials their BD teams need to see
Run outreach and secure meetings
Including partnering conferences, run for you
Negotiate and close
Kept moving until terms are agreed
We become your BD function, without the overhead of hiring one.
A biotech BD consultant helps life sciences companies identify potential licensing partners, develop pitch materials, manage outreach, and negotiate deal terms. JustPartnering provides end-to-end business development and licensing support for biotech and research teams, from target list to signed agreement. Our hourly model has no retainer, success fee, or minimum commitment, so our advice stays focused on getting you the right deal.
Not sure which partners to approach first?
A target list shows who is actively in-licensing in your space and the named contact at each one.
Every target list we build starts in Biocontacts.
Biocontacts is JustPartnering’s partnering database. Since 2007 we have recorded which life science companies in-license, what each one wants to bring in, and who handles it. Your outreach goes to companies with a stated interest in assets like yours, through a named contact.
- What they want to in-license
- Therapeutic areas, modalities, and indications.
- Stages they will look at
- The development stages each company considers.
- Notes from our meetings
- Interests refreshed from our own meetings: 300+ face-to-face a year, and many more held virtually.
- Who handles it
- The BD, external innovation, and search and evaluation contacts, re-checked as people move.
Mid-size oncology developer
- Oncology
- ADC
- Solid tumours
- Preclinical to Phase 1
Looking to in-license
Preclinical to early clinical ADC assets in solid tumours, from Asia-Pacific and European originators.
Last confirmed at a partnering meeting
Head of Search & Evaluation
BD contact
Fit for a preclinical ADC in solid tumours
- Wants ADCs
- Focused on solid tumours
- Takes preclinical assets
- Companies that in-license
- 2,500+
- Pharma, biotech, medical device, and animal health.
- BD contacts mapped
- 4,000+
- The people whose job is to review assets like yours.
- Partnering keywords
- 1,000+
- Mapped to what each company wants.
- Updates
- Weekly
- Built through partnering work since 2007.
How we get your asset in front of the right partners
From positioning through to signed deal, we support every stage of the partnering process.
Identify the right partners
Receive a prioritised target list of in-licensing companies, filtered to fit your asset.
- Includes contact names, job titles, and email addresses, ready to action
- Ranked strong, good, or possible, so you know who to approach first
- Delivered as a working document for independent use, or with our support
Most curated target lists cost US$700–$2,000, ready within 3 days
Contains a ranked list of companies in-licensing assets in your therapeutic area or disease indication and at your stage of development.
Get a target listBuild a partner-ready pitch
A pitch built for in-licensing teams: TPP-aligned and competitively positioned.
- Positioned against the competitive landscape, not just describing the science
- Structured around what pharma and biotech in-licensing teams look for
- Suitable for partnering conferences, investor meetings, and email outreach
Run targeted outreach and secure meetings
We reach out to the right-fit companies on your behalf, or hand you the list to run yourself.
- Relevant in-licensing contacts selected by role and in-licensing activity
- All correspondence copied into a shared folder so you have full visibility
- Follow-up rounds managed for you, because that is where most outreach stalls
Partnering conferences, run for you
We attend 4+ major conferences a year, including BIO and BIO-Europe, and handle meetings on your behalf.
- Active representation: we secure one-on-one meetings for your asset
- Passive option: we upload your profile and report on inbound interest
- Conference and travel costs shared across clients to keep costs low
End-to-end negotiation and deal close
We coordinate term sheets, diligence, and contracting, keeping both sides moving toward close.
- Term sheet, diligence, and contract workstreams tracked in one place
- Data room setup and management handled if needed
- Hand off as much or as little as you need
Most outreach stalls during follow-up, not the first email. We manage every round to keep it moving.
How we work versus going it alone
What running a partnering process with internal resource costs you, versus engaging JustPartnering.
| Factor | On your own | With JustPartnering |
|---|---|---|
| Cost model | No upfront cost, but significant internal time diverted from R&D. | Hourly. No retainer, no success fees, no minimum commitment. |
| Timeline | No defined process: momentum depends on whoever has spare capacity that week. | Every viable partner approached in parallel, with follow-up on a schedule that doesn’t depend on who has time that week. |
Built on partnering work since 2007.
- 50+
- Assets progressed from lab to clinic
- 19+
- Years of partnering experience
Common questions
What is Biocontacts?
When is the right time to start a partnering process?
What do pharma companies look for when in-licensing?
How long does a biotech licensing deal take to close?
What materials do I need for a biotech partnering process?
How do biotech licensing deals work?
Ready to move your asset forward?
Talk to a senior advisor about your asset and what partnering could look like. No brief required. Tell us where you’re stuck.
Let’s talk